Seven Eight Capital’s AnaptysBio ANAB Stock Holding History

Seven Eight Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-9,600	Closed	-$999K	–	458
2018 Q1	$999K	Buy	+9,600	New	+$1.08M	0.08%	228

Other funds holding ANAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Seven Eight Capital's ANAB Position: Q2 2018 in Review

Seven Eight Capital sold out of AnaptysBio (ANAB) in Q2 2018, closing a stake of 9,600 shares — an estimated $999K sold.

Seven Eight Capital first reported a position in ANAB in Q1 2018 and held it in 1 quarter. The position peaked at $999K in Q1 2018. 124 funds tracked by Wall St. Rank hold ANAB as of Q2 2018.

Seven Eight Capital reported no remaining AnaptysBio position as of Q2 2018 after selling out during the quarter.
Seven Eight Capital sold 9,600 AnaptysBio shares in Q2 2018, an estimated $999K.
Seven Eight Capital first reported a position in AnaptysBio in Q1 2018 and held it in 1 quarter.
Seven Eight Capital's AnaptysBio position peaked at $999K in Q1 2018.
124 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2018.

Based on Seven Eight Capital's 13F filing for Q2 2018, filed 7 Aug 2018.